Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach

• Published in: Strahlentherapie und Onkologie Vol. 198; no. 7; pp. 654 - 662
• Main Authors: Fleischmann, Maximilian, Diefenhardt, Markus, Trommel, Martin, Scherf, Christian, Ramm, Ulla, Chatzikonstantinou, Georgios, Fokas, Emmanouil, Rödel, Claus, Tselis, Nikolaos
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2022; Springer Nature B.V
• Subjects: Cancer; Cancer therapies; Colorectal cancer; Frailty; Magnetic resonance imaging; Medical imaging; Medicine; Medicine & Public Health; Older people; Oncology; Original; Original Article; Pelvis; Radiation dosage; Radiation therapy; Radiotherapy; Rectum; Surgery; Toxicity; Tumors; Endorectal; Organ preservation; Rectal cancer; Nonoperative management; Brachytherapy; Endoluminal; Radiotherapy; Complete response
• ISSN: 0179-7158; 1439-099X
• DOI: 10.1007/s00066-022-01931-4

Purpose As the population ages, the incidence of rectal cancer among elderly patients is rising. Due to the risk of perioperative morbidity and mortality, alternative nonoperative treatment options have been explored in elderly and frail patients who are clinically inoperable or refuse surgery. Methods Here we present technical considerations and first clinical experience after treating a cohort of six rectal cancer patients (T1‑3, N0‑1, M0; UICC stage I-IIIB) with definitive external-beam radiation therapy (EBRT) followed by image-guided, endorectal high-dose-rate brachytherapy (HDR-BT). Patients were treated with 10–13 × 3 Gy EBRT followed by HDR-BT delivering 12–18 Gy in two or three fractions. Tumor response was evaluated using endoscopy and magnetic resonance imaging of the pelvis. Results Median age was 84 years. All patients completed EBRT and HDR-BT without any high-grade toxicity (> grade 2). One patient experienced rectal bleeding (grade 2) after 10 weeks. Four patients (67%) demonstrated clinical complete response (cCR) or near cCR, there was one partial response, and one residual tumor and hepatic metastasis 8 weeks after HDR-BT. The median follow-up time for all six patients is 42 weeks (range 8–60 weeks). Sustained cCR without evidence of local regrowth has been achieved in all four patients with initial (n)cCR to date. Conclusion Primary EBRT combined with HDR-BT is feasible and well tolerated with promising response rates in elderly and frail rectal cancer patients. The concept could be an integral part of a highly individualized and selective nonoperative treatment offered to patients who are not suitable for or refuse surgery.